WOBURN, Mass. , March 9, 2021 /PRNewswire/ — Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts , announced a deal with Shanghai Haohai Biological Technology Ltd. (“Haohai”) that will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eirion’s products for the territory of China in exchange for an upfront payment in the amount of $8 million .…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.